(Q37260055)

English

The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer

scientific article published on 24 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1 reference

3 April 2019

multicenter study report

1 reference

PubMed publication ID

The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

0 references

prostate neoplasm

1 reference

3 April 2019

physiologic monitoring

1 reference

PubMed publication ID

watchful waiting

1 reference

PubMed publication ID

object named as

Erik Holmberg

3

0 references

4

object named as

Lars Holmberg

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1

object named as

Ola Bratt

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

Stefan Carlsson

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Eva Johansson

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Andreas Josefsson

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Annika Nilsson

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Maria Nyberg

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

David Robinsson

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Jonas Sandberg

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Dag Sandblom

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Pär Stattin

12

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

publication date

24 July 2013

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1 October 2013

1 reference

3 April 2019

Scandinavian journal of urology

2 references

Europe PubMed Central

PMC publication ID

19 August 2017

3 April 2019

47

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

347-355

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

6 September 2017

Prostate cancer mortality following active surveillance versus immediate radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

6 September 2017

Radical prostatectomy versus observation for localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

6 September 2017

Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

6 September 2017

Active surveillance for prostate cancer: a systematic review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

6 September 2017

Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

6 September 2017

National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

6 September 2017

Outcomes of active surveillance for men with intermediate-risk prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

6 September 2017

Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

6 September 2017

'Insignificant' prostate cancer on biopsy: pathologic results from subsequent radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

6 September 2017

The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

6 September 2017

The influence of finasteride on the development of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

6 September 2017

Medium-term outcomes of active surveillance for localised prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

14 September 2017

Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

14 September 2017

High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

14 September 2017

Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

26 June 2018

Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

3 September 2018

Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

3 September 2018

Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

3 September 2018

Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

3 September 2018

Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

3 September 2018

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

3 September 2018

Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

3 September 2018

The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

3 September 2018

Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

3 September 2018

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

3 September 2018

Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

3 September 2018

Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

3 September 2018

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3810035

3 September 2018

1 reference

https://api.crossref.org/works/10.3109%2F21681805.2013.813962

21 January 2018

The proportion of free PSA and upgrading of biopsy Gleason score after radical prostatectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23883427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23883427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of 5α-Reductase Inhibitors on Men Followed by Active Surveillance for Prostate Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23883427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Should we really consider Gleason 6 prostate cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23883427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of a structured report of functional prostate magnetic resonance imaging in patients with suspicion for prostate cancer or under active surveillance

1 reference

https://pubmed.ncbi.nlm.nih.gov/23883427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23883427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23883427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23883427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of histological disease progression in untreated, localized prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23883427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features

1 reference

https://pubmed.ncbi.nlm.nih.gov/23883427

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3109/21681805.2013.813962

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37260055&oldid=2163586935"